Abstract: Compounds having the formula (1): 1

Abstract: Compounds having the formula (1): 1

Abstract: The present invention relates to a method for purifying a calcium ion-binding protein by cation exchange chromatography. The present invention provide a method for isolating and purifying a calcium ion-binding protein in a simple and efficient manner from a liquid sample containing a calcium ion-binding protein and contaminants without any pretreatment such as addition of a chelating agent. More specifically, the present invention relates to a method for purifying a calcium ion-binding protein which comprises contacting said protein with a cation exchange carrier in the presence of calcium ions to let the said protein be adsorbed to the carrier, and after washing, eluting said protein, and to a calcium ion-binding protein having substantially no contaminants obtained by the method of the present invention.

Abstract: This invention relates to pyridazine derivatives represented by the formula (1): 1

Abstract: This invention relates to pyridazine derivatives represented by the formula (1): wherein R1 represents a lower alkoxyl group, a lower alkylthio group or a halogen atom; R2 represents H, a lower alkoxyl group, a lower alkylthio group or a halogen atom; R3 represents a lower alkyl or lower alkenyl group, which may be substituted by one or more OHs, CNs, lower cycloalkyl groups, (substituted) aromatic groups or (substituted) carbamoyl groups; R4 represents COOH, a lower alkoxycarbonyl group, a (substituted) carbamoyl group, a (substituted) amino group, or a (substituted) ureido group; and the dashed line indicates that the carbon-carbon bond between the 4-position and the 5-position is a single bond or a double bond, or salts thereof; and also to medicines containing them as effective ingredients.

Abstract: This invention relates to pyridazine derivatives represented by the formula (1): wherein R1 represents a (substituted) aryl group, R2 represents a phenyl group substituted at 4-position by a lower alkoxyl group or a lower alkylthio group, R3 represents a lower alkoxyl group, a halogenated lower alkyl group, a lower cycloalkyl group, a (subsituted) aryl group, a (substituted) aryloxy group, a (substituted) nitrogen-containing heterocyclic ring residue, a (substituted) aminocarbonyl group or a lower alkylcarbonyl group, A represents a single bond, a lower alkylene group or a lower alkenylene group, X represents O or S, and the dashed line indicates that the carbon-carbon bond between the 4-position and the 5-position is a single bond or a double bond, or salts thereof; and also to medicines containing them as effective ingredients.

Abstract: A human placenta-derived antiocoagulating substance is prepared by homogenizing a human plancenta, subjecting the resulting homogenate to centrifugal separation, extracting the thus-obtained sediment with a chelating agent, and then separating and purifying the extract. The substance has a molecular weight of 73,000.+-.2,000 as measured in reduced and non-reduced states by SDS-polyacrylamide gel electrophoresis. Its isoelectric point ranges from 6.2 to 6.6 as measured by isoelectric column electrophoresis using an ampholyte. It is inactivated by a heat treatment at 50.degree. C. for 30 minutes, is stable in a pH range of 5.5-8.5 (37.degree. C.) and is also stable in plasma at 37.degree. C. for 15 minutes. It can prolong the recalcification time, prothrombin time and activated partial thromboplastic time.

Abstract: A method for stabilizing a tissue plasminogen activator which involves adding to an aqueous solution or powder containing a tissue plasminogen activator an effective amount of a purified gelatin is disclosed. A stable aqueous solution or powder which contains a tissue plasminogen activator and an effective amount of a purified gelatin is also disclosed. The method and composition eliminate the problem of adsorption of tissue plasminogen activator to various laboratory equipment, and also prevent the conversion of the single-chain tissue plasminogen activator into a double-chain tissue plasminogen activator.

Abstract: A plasminogen activator obtained from a tissue cultured liquor of human normal tissue derived cells, e.g., human embryonic derived cells, human placenta derived cells etc., and having the following properties:(a) molecular weight measured by gel filtration: 63,000.+-.10,000,(b) isoelectric point: 7.0-8.5,(c) affinity to fibrin: present,(d) affinity to concanavalin A: present,(e) optimum pH: 7-9.5, and(f) stability: does not lose activity at 60.degree. C. for 10 hours but loses about 5% of activity at pH 2-3 at 98.degree. C. for a minute; a process for the production of the aforesaid plasminogen activator; and a thrombolytic composition containing the aforesaid plasminogen activator as an active ingredient are disclosed.